Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesc Alamon-Reig

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 29, 2024
Esophageal involvement in DPP4 inhibitor-associated bullous pemphigoidMagí Brufau-Cochs, Francesc Alamon-Reig, Mar Luque-Luna, et al.
Pediatric Dermatology|March 18, 2023
Linear juvenile dermatomyositis: A segmental manifestationFrancesc Alamon-Reig, Anna Sánchez-Puigdollers, Gloria Juan-Carpena, et al.
JAMA Dermatology|February 22, 2023
Treatment of Porokeratosis Ptychotropica With a Topical Combination of Cholesterol and SimvastatinMarta Albanell-Fernández, Mar Luque-Luna, Carmen López-Cabezas, et al.
Photodermatology, Photoimmunology & Photomedicine|July 28, 2021
Acquired erythropoietic uroporphyria secondary to myeloid malignancy: A case report and literature reviewLaura Serra-García, Daniel Morgado-Carrasco, Amanda Isabel Pérez-Valencia, et al.
International Journal of Dermatology|October 11, 2020
Digital ischemia triggered by coronavirus disease 2019 in a patient under cemiplimab treatmentLaura Serra-García, Xavier Bosch-Amate, Francesc Alamon-Reig, et al.
Journal of the American Academy of Dermatology|October 16, 2023
Use of omalizumab is associated with improvement of pruritic skin disorders induced by immune checkpoint inhibitors: A retrospective cohort from the European Task Force of Dermatology for Cancer patientsFrancesc Alamon-Reig, Xavier Bosch-Amate, Priscila Giavedoni, et al.
Acta Dermato-Venereologica|September 5, 2024
Cutaneous Adverse Reactions to Apalutamide: Case Series with Clinical and Pathological CorrelationsJavier Gil-Lianes, Victoria Amat-Samaranch, Priscila Giavedoni, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Analysis of dermoscopic changes of blue nevi on digital follow-up: A 21-year retrospective cohort studyFrancesc Alamon-Reig, Marc Combalia, Raquel Albero-González, et al.
Cancers|February 13, 2026
Chemoprevention in Skin Cancer: What Advice?Ariadna Ortiz-Brugués, Carmen Orte Cano, Lluis Corbella, et al.
Acta Dermato-Venereologica|May 21, 2026
Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case SeriesCecilia Tejero-García, Francesc Alamon Reig, Xavier Bosch-Amate, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 29, 2024
Esophageal involvement in DPP4 inhibitor-associated bullous pemphigoidMagí Brufau-Cochs, Francesc Alamon-Reig, Mar Luque-Luna, et al.
Pediatric Dermatology|March 18, 2023
Linear juvenile dermatomyositis: A segmental manifestationFrancesc Alamon-Reig, Anna Sánchez-Puigdollers, Gloria Juan-Carpena, et al.
JAMA Dermatology|February 22, 2023
Treatment of Porokeratosis Ptychotropica With a Topical Combination of Cholesterol and SimvastatinMarta Albanell-Fernández, Mar Luque-Luna, Carmen López-Cabezas, et al.
Photodermatology, Photoimmunology & Photomedicine|July 28, 2021
Acquired erythropoietic uroporphyria secondary to myeloid malignancy: A case report and literature reviewLaura Serra-García, Daniel Morgado-Carrasco, Amanda Isabel Pérez-Valencia, et al.
International Journal of Dermatology|October 11, 2020
Digital ischemia triggered by coronavirus disease 2019 in a patient under cemiplimab treatmentLaura Serra-García, Xavier Bosch-Amate, Francesc Alamon-Reig, et al.
Journal of the American Academy of Dermatology|October 16, 2023
Use of omalizumab is associated with improvement of pruritic skin disorders induced by immune checkpoint inhibitors: A retrospective cohort from the European Task Force of Dermatology for Cancer patientsFrancesc Alamon-Reig, Xavier Bosch-Amate, Priscila Giavedoni, et al.
Acta Dermato-Venereologica|September 5, 2024
Cutaneous Adverse Reactions to Apalutamide: Case Series with Clinical and Pathological CorrelationsJavier Gil-Lianes, Victoria Amat-Samaranch, Priscila Giavedoni, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Analysis of dermoscopic changes of blue nevi on digital follow-up: A 21-year retrospective cohort studyFrancesc Alamon-Reig, Marc Combalia, Raquel Albero-González, et al.
Cancers|February 13, 2026
Chemoprevention in Skin Cancer: What Advice?Ariadna Ortiz-Brugués, Carmen Orte Cano, Lluis Corbella, et al.
Acta Dermato-Venereologica|May 21, 2026
Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case SeriesCecilia Tejero-García, Francesc Alamon Reig, Xavier Bosch-Amate, et al.
Pageof 4